Harvard Bioscience, Inc. (HBIO) Earnings History
Net Loss28 years of earnings data (1998–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Harvard Bioscience, Inc. (HBIO) Earnings Overview
As of June 30, 2026, Harvard Bioscience, Inc. (HBIO) reported trailing twelve-month net income of -$10M, reflecting -357.1% year-over-year growth. The company earned $-2.19 per diluted share over the past four quarters, with a net profit margin of -65.5%.
Looking at the long-term picture, HBIO's historical earnings data spans multiple years. The company achieved its highest annual net income of $19M in fiscal 2010.
Harvard Bioscience, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ITRN ($60M net income, 16.1% margin), BEAT (-$20M net income), MLAB ($7M net income, 2.7% margin), HBIO has room to improve margins relative to the peer group. Compare HBIO vs ITRN →
HBIO Earnings vs Peers
Earnings metrics vs comparable public companies
HBIO Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$57M | -357.1% | $-629,000 | $-12.80 | -65.5% | -0.7% |
| 2024 | -$12M | -263.3% | -$6M | $-2.80 | -13.2% | -6.6% |
| 2023 | -$3M | +64.1% | $2M | $-0.81 | -3.0% | 1.7% |
| 2022 | -$10M | -3204.2% | -$7M | $-2.30 | -8.4% | -6.1% |
| 2021 | $-288,000 | +96.3% | $2M | $-0.07 | -0.2% | 1.7% |
| 2020 | -$8M | -66.6% | $221,000 | $-2.00 | -7.6% | 0.2% |
| 2019 | -$5M | -35.4% | $377,000 | $-1.20 | -4.0% | 0.3% |
| 2018 | -$3M | -300.2% | $984,000 | $-0.95 | -2.9% | 0.8% |
| 2017 | $-865,000 | +79.9% | $-101,000 | $-0.25 | -0.8% | -0.1% |
| 2016 | -$4M | +77.4% | -$3M | $-1.30 | -4.1% | -2.9% |
| 2015 | -$19M | -908.5% | -$2M | $-5.70 | -17.5% | -1.6% |
| 2014 | $2M | +228.7% | $7M | $0.70 | 2.2% | 6.1% |
| 2013 | -$2M | -177.2% | $2M | $-0.57 | -1.7% | 1.5% |
| 2012 | $2M | -37.8% | $3M | $0.80 | 2.1% | 2.8% |
| 2011 | $4M | -80.0% | $6M | $1.30 | 3.5% | 5.6% |
| 2010 | $19M | +162.9% | $10M | $6.50 | 17.6% | 9.4% |
| 2009 | $7M | +332.3% | $8M | $2.40 | 8.4% | 9.4% |
| 2008 | $2M | +223.6% | $8M | $0.50 | 1.9% | 9.6% |
| 2007 | -$1M | +42.2% | $10M | $-0.43 | -1.6% | 11.4% |
| 2006 | -$2M | +92.7% | $9M | $-0.75 | -3.1% | 11.4% |
| 2005 | -$32M | -1468.7% | $8M | $-10.40 | -47.3% | 11.8% |
| 2004 | $2M | -45.3% | $4M | $0.70 | 2.5% | 4.7% |
| 2003 | $4M | +477.7% | $8M | $1.40 | 4.9% | 8.8% |
| 2002 | $737,327 | +114.2% | $2M | $0.30 | 1.3% | 2.9% |
| 2001 | -$5M | +89.6% | -$5M | $-2.00 | -12.7% | -11.4% |
| 2000 | -$50M | -69.5% | -$10M | $-62.30 | -163.1% | -33.8% |
| 1999 | -$29M | -41536.5% | $1M | $-52.50 | -112.4% | 4.3% |
| 1998 | $71,000 | - | $2M | $-0.10 | 0.6% | 19.8% |
Download Data
Export HBIO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
28+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HBIO — Frequently Asked Questions
Quick answers to the most common questions about buying HBIO stock.
What is HBIO earnings per share (EPS)?
HBIO trailing twelve-month (TTM) diluted EPS is $-2.19, reflecting -357.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1998 to 2025 is available in the table on this page.
What is Harvard Bioscience, Inc.'s net income?
Harvard Bioscience, Inc. (HBIO) trailing twelve-month net income is $-10M as of 2025. Earnings declined -357.1% year-over-year.
Is HBIO profitable?
HBIO is not currently profitable on a TTM basis, reporting a net loss of $-10M. Net margin is -65.5%. Investors should monitor for a return to profitability.
What is HBIO's earnings growth rate?
HBIO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1998 to 2025.
What are HBIO's profit margins?
Harvard Bioscience, Inc. net profit margin is -65.5%, operating margin is -0.7%, and gross margin is +53.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -147.1%.
Is HBIO growing earnings?
HBIO earnings are declining — EPS fell -357.1% year-over-year. TTM net income dropped to $-10M. This contrasts with the 5-year CAGR of N/A.
What was HBIO's best earnings year?
Harvard Bioscience, Inc.'s highest annual net income on record is $19M, achieved in fiscal year 2010. Earnings history on this page spans 1998 to 2025 and includes all annual and quarterly figures.
What were HBIO's earnings last quarter?
HBIO's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-0.77. For a full breakdown of all quarters, see the quarterly earnings table on this page.